| __timestamp | BioMarin Pharmaceutical Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 94231000 |
| Thursday, January 1, 2015 | 634806000 | 146394000 |
| Friday, January 1, 2016 | 661905000 | 188272000 |
| Sunday, January 1, 2017 | 610753000 | 166707000 |
| Monday, January 1, 2018 | 696328000 | 401843000 |
| Tuesday, January 1, 2019 | 715007000 | 560909000 |
| Wednesday, January 1, 2020 | 628116000 | 722343000 |
| Friday, January 1, 2021 | 628793000 | 771182000 |
| Saturday, January 1, 2022 | 649606000 | 877090000 |
| Sunday, January 1, 2023 | 746773000 | 877387000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. have been at the forefront of this race. From 2014 to 2023, BioMarin's R&D expenses grew by approximately 62%, peaking in 2023. Meanwhile, Sarepta's investment surged by an impressive 830%, reflecting its aggressive pursuit of cutting-edge therapies.
BioMarin consistently invested over $600 million annually, with a notable increase in 2023, reaching nearly $750 million. Sarepta, starting from a modest base, dramatically increased its R&D budget, surpassing BioMarin in 2020 and maintaining a lead with over $870 million in 2023. This trend underscores the dynamic nature of the biotech sector, where strategic R&D investments can redefine market positions and drive future growth.
AbbVie Inc. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.
R&D Insights: How Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. Allocate Funds
Comparing Innovation Spending: Zoetis Inc. and BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Comparing Innovation Spending: Incyte Corporation and Sarepta Therapeutics, Inc.
BioMarin Pharmaceutical Inc. or Pharming Group N.V.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs Halozyme Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Sarepta Therapeutics, Inc. and Alkermes plc
Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending